Key Highlights
- Cystic Fibrosis Foundation commits $15M to ReCode Therapeutics for lung-targeted gene editing collaboration with Intellia Therapeutics.
- ReCode focuses on lipid nanoparticle delivery systems for lung stem cell targeting, critical for permanent gene correction.
- Intellia’s therapy aims to correct CFTR gene nonsense mutations affecting individuals not eligible for CFTR modulators.
- Investment builds on a separate $15M CF Foundation funding for messenger RNA therapy now in clinical trials.
- The initiative targets transformative treatments for CF, particularly for patients unable to benefit from current modulators.
Source: Business Wire
Notable Quote
- “Gene editing is a promising, complex technology, which will take many years to develop into a therapy for people with CF. By investing in this research now, we are laying the foundation to develop what we hope will be a transformative treatment for people with CF, especially those who can’t take CFTR modulators.” — Steven Rowe, MD – Executive Vice President and Chief Scientific Officer at Cystic Fibrosis Foundation
SoHC's Take
This investment underscores the Cystic Fibrosis Foundation’s commitment to pioneering treatments for all individuals with CF, especially those underserved by current therapies. By pairing ReCode’s advanced delivery systems with Intellia’s gene editing expertise, the collaboration has the potential to address critical gaps in CF care. The parallel development of mRNA therapy further emphasizes a diversified approach to tackling this complex disease, potentially revolutionizing the therapeutic landscape for CF.
